Neumora Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neumora Therapeutics, Inc. on August 14, 2026. The filing primarily addresses two events: the announcement of financial results for the second quarter ended June 30, 2026, and a significant leadership transition within the company's executive management.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the full financial results for the second quarter of 2026. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing states that the information in the press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Material Changes
The most significant material change disclosed in this filing is the leadership transition effective August 14, 2026:
- Paul L. Berns: Transitioned from Chief Executive Officer to Executive Chairperson of the Board of Directors.
- Joshua Pinto, Ph.D.: Succeeded Mr. Berns as Chief Executive Officer while continuing to serve as President. Additionally, Dr. Pinto was appointed as a Class III director, with a term expiring at the 2029 Annual Meeting of Stockholders.
The Board approved these changes on August 12, 2026.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, or risk factors regarding the company's future operations or financial condition. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2026 financial figures, including cash burn rate and remaining liquidity.
- Verify the strategic rationale for the leadership transition and any associated compensation arrangements for Dr. Pinto.
- Confirm the status of the company's clinical pipeline and any updates to development timelines mentioned in the press release.
- Check for any new material agreements or contingencies disclosed in the full press release text.